.svg){kind=small}
Strategy
· EPISODE
241
Build-to-Buy and Option Structures
M&A is inherently risky, but the rewards of a successful deal can exponentially grow a company overnight. There are many things to consider before closing a transaction, and big companies are finding new deal structures to minimize risks when doing acquisitions. In this episode, Finn Haley, SVP of Corporate Development at Edwards Lifesciences, discusses the build-to-buy option structure they use in the healthcare industry.
_Easy-Resize.com.avif)
W7ANHkbtYow
837457536
Finn Haley
Finn Haley is the Senior Vice President of Corporate Development at Edwards Lifesciences, where he leads the execution of acquisitions, divestitures, venture capital investments, and strategic partnerships. With over 20 years of experience in healthcare and medtech, Finn has been instrumental in driving inorganic growth and integrating acquisitions. Prior to joining Edwards in 2020, he spent nearly 14 years at 3M in various corporate development and business strategy roles, focusing on healthcare. Finn's career began in investment banking, with significant stints at Piper Jaffray and Duff & Phelps, contributing to over 60 successful deals.
TAKE THE NEXT STEP
Turn what you heard into a repeatable M&A practice.
Explore the Buyer-Led M&A Certification for practical frameworks, tools, and decision-making habits you can apply on your next deal.
.svg){kind=small}
Where buy-side M&A learns from itself. The Buyer-Led M&A operating standard built from a decade of practitioner interviews.
DEALPILOT
LEARN
COMPANY